In 1996 a laboratory at the Institute of Pharmacology of the Russian Academy of Medical Sciences reported a cyclic dipeptide in rat brain tissue and attached a number to it: 2.8 nmol per gram of wet brain, measured by gas chromatography. Fourteen years later the same laboratory published a figure of 29.2 nmol per gram for whole rat brain. Both numbers describe the same molecule, cycloprolylglycine.
A tenfold disagreement inside one research programme is the first thing worth knowing here. The second is what the molecule is supposed to explain. Noopept is laboratory shorthand for N-phenylacetyl-L-prolylglycine ethyl ester, and the claim attached to it is a prodrug claim: the ester is cleaved in the body, and what actually reaches neural tissue is a smaller cyclic dipeptide. That proposed metabolite is cycloprolylglycine.
What the cycloprolylglycine metabolite hypothesis about noopept actually claims
PubChem lists the parent compound under identifier 180496, with molecular formula C17H22N2O4, a molecular weight of 318.4 and the systematic name ethyl 2-[[(2S)-1-(2-phenylacetyl)pyrrolidine-2-carbonyl]amino]acetate. That record carries a single registry number, 157115-85-0.
The proposed metabolite is smaller and far more polar: formula C7H10N2O2, molecular weight 154.17, a calculated partition coefficient of minus 0.6 and zero rotatable bonds. The identifier picture here is less tidy. PubChem holds the cyclic dipeptide under more than one record, one with unspecified stereochemistry and one specified as the 8aS configuration, and the stereospecified record carries two registry numbers rather than one. A single CAS number quoted for this molecule is a selection among records that PubChem itself does not merge.
The prodrug proposal separates into three claims that stand or fall independently: that cycloprolylglycine occurs naturally in brain tissue, that the parent ester is converted into it, and that the metabolite rather than the parent carries the pharmacology. The three rest on different evidence.
How cycloprolylglycine was first detected in rat brain
The 1996 report in FEBS Letters combined high-performance liquid chromatography (HPLC), gas chromatography and chromatography-mass spectrometry to identify the cyclic dipeptide in rat brain. The authors reported that synthetic material showed antiamnesic activity in a passive avoidance procedure, and proposed that its presence in brain pointed to a previously unrecognised route of memory regulation.
The metabolism paper followed in 1997 in the European Journal of Drug Metabolism and Pharmacokinetics. The parent ester was not detectable in rat brain one hour after intraperitoneal injection, down to the limit of detection of the HPLC method used. Three candidate breakdown products, phenylacetic acid, prolylglycine and cyclo-prolylglycine, were found in the brains of treated animals and also in untreated control animals. Only the cyclic dipeptide rose, roughly 2.5-fold, after the parent was given. Conversion in the presence of plasma and brain enzymes was also shown in vitro.
Two things follow from that experiment, and only two. The parent sat below detection in brain tissue, and one of its possible breakdown products increased. That pattern fits a prodrug relationship. It also fits rapid clearance of the parent, cyclisation occurring mainly in plasma, or a detection limit higher than the concentration present. The experiment did not separate those accounts.
Telling a parent ester apart from its cyclic breakdown product in a chromatogram needs retention time and mass together, which is why work of this kind runs against a characterised noopept analytical reference standard and synthetic cyclic dipeptide of declared stereochemistry.
Why the reported brain concentration figures do not agree
The 2010 localisation study from the same institute reported uneven distribution across brain regions in rats: 29.2 nmol per gram in whole brain, 38.9 in cortex and 126.4 in hippocampus. About 60 percent of the peptide appeared in the nuclear subcellular fraction.
Set that figure beside the 2.8 nmol per gram reported in 1996 and the discrepancy is an order of magnitude. Extraction chemistry, detectors and animal cohorts all move an absolute tissue concentration. The point is narrower: there is no settled endogenous concentration for this molecule, and no independent replication of either figure was located.
There is a further analytical wrinkle. Cyclic dipeptides of this class, the diketopiperazines, are not exclusive to mammalian tissue. A 2018 clinical study in Nutrients measured the same cyclic glycine-proline in cerebrospinal fluid and reported that the molecule was already present in the blackcurrant preparation given to participants. A compound occurring in plant material has a possible exogenous contribution to tissue concentration, which complicates the word endogenous rather than refuting it.
What the AMPA receptor and TrkB experiments measured
The mechanistic case built slowly and in one place. A 2016 paper in Doklady Biochemistry and Biophysics reported that the cyclopeptide at one micromolar enhanced transmembrane AMPA currents in rat cerebellar Purkinje cells, and described it as an endogenous positive modulator of AMPA receptors, linking that to earlier work on brain-derived neurotrophic factor in culture.
Two blockade studies followed. In 2020 the same group reported that DNQX, an AMPA receptor antagonist, and K252a, a Trk receptor inhibitor, each prevented the anxiolytic effect in rodents. In 2022 they reported that DNQX, the non-competitive blocker GYKI 52466 and K252a each prevented the neuroprotective effect in vitro. Blockade experiments speak to necessity and are silent about sufficiency: they show an intact AMPA and Trk path is required, not that the peptide binds either receptor. No binding constant is reported anywhere in the series.
A separate 2020 study looked for mitogenic activity in HEK293 and SH-SY5Y cells and found none, reporting a reduction in early apoptotic cells instead. That negative result was published openly.
One 2022 finding does not sit comfortably inside a clean prodrug account. A group at the Research Center of Neurology in Moscow, working in rat hippocampal slices, reported that the parent dipeptide itself increased firing of GABAergic interneurons, and that alpha-bungarotoxin and methyllycaconitine, both selective for the alpha7 nicotinic acetylcholine receptor, almost completely abolished the effect. In an acute slice the parent molecule is doing something of its own.
The same molecule arrives from a completely different direction
Outside the Russian literature the identical cyclic dipeptide is studied under a different name and a different origin story. Work from the University of Auckland treats cyclic glycine-proline as a metabolite of insulin-like growth factor 1, not of any synthetic ester.
A 2014 paper in Scientific Reports reported that the cyclic peptide alters binding of IGF-1 to its binding protein IGFBP-3, promoting IGF-1 activity when the growth factor is scarce and damping it when abundant. A 2019 study measured the peptide in plasma from 34 stroke patients and 50 age-matched controls, finding the molar ratio to IGF-1 lower in patients at baseline and rising over 90 days. The 2018 cerebrospinal fluid study involved 11 participants.
These are small datasets, described by their authors as exploratory biomarker work rather than as mechanism. Their relevance here is indirect but real: they give the molecule an endogenous route, via cleavage of a growth factor, with no synthetic compound in it.
| Line of evidence | What was measured | O que não resolve |
|---|---|---|
| 1996 identification | Presence in rat brain, three chromatographic methods | Absolute concentration; independent replication |
| 1997 metabolism | Parent below detection, cyclic product raised 2.5-fold | Where cyclisation occurs; whether the parent is inactive |
| 2016 electrophysiology | Enhanced AMPA currents at one micromolar | Binding site, affinity, selectivity |
| 2020 and 2022 blockade | Antagonists abolish two measured effects | Sufficiency; order of events in the pathway |
Where the evidence stops short of an established mechanism
Concentration of authorship is the largest structural weakness. Almost every primary paper naming the cyclopeptide as a mnemotropic agent carries an affiliation to the Zakusov Research Institute of Pharmacology in Moscow, and most appear in two translated short-format journals. That is a coherent programme rather than a distributed field.
A alegação relativa ao metabolito também se generaliza de um modo que enfraquece a sua especificidade. Um artigo de 2022 sobre um éster diferente contendo prolina, o GZK-111, descreveu quatro produtos de biotransformação e voltou a identificar entre eles o mesmo dipéptido cíclico. Um metabolito comum a uma série química é um produto plausível dessa série, não uma prova de que seja a espécie ativa de qualquer um dos seus membros.
A lacuna mais importante é a humana. Não foi localizado nenhum estudo farmacocinético que mostre que o ciclopéptido aumenta no plasma ou no líquido cefalorraquidiano humanos após o éster original, e as medições de Auckland dizem respeito, pelo contrário, ao péptido proveniente da clivagem do fator de crescimento. Lida de forma rigorosa, a literatura sustenta uma afirmação restrita: o dipéptido cíclico é detetável no cérebro de roedores, aumenta depois de o éster original entrar no animal, e os seus efeitos em dois ensaios em roedores exigem a sinalização AMPA e Trk intacta. Cada passo para além disso é uma hipótese que ainda depende de uma experiência.
Perguntas frequentes
O que é o metabolito cicloprolilglicina do noopept?
É um dipéptido cíclico, de fórmula C7H10N2O2 e massa molecular 154,17, formado por ciclização após a clivagem da ligação éster original. Um estudo de 1997 em ratos verificou que o composto original estava abaixo do limite de deteção no cérebro, enquanto este produto aumentava cerca de 2,5 vezes, o que está na origem da proposta de pró-fármaco. A conversão continua por demonstrar em seres humanos.
A cicloprolilglicina é um péptido cerebral endógeno?
Foi descrita em cérebro de rato não tratado em 1996 e novamente num estudo regional de 2010, pelo que está presente em tecido que não recebeu nada. Subsistem duas complicações: as duas concentrações descritas para o cérebro inteiro diferem cerca de dez vezes, e o mesmo dipéptido cíclico ocorre em material vegetal, pelo que não se pode excluir um contributo alimentar para os níveis tecidulares.
Quanta cicloprolilglicina existe no tecido cerebral de rato?
Os valores publicados divergem. O artigo de identificação de 1996 descreveu 2,8 nmol por grama de cérebro húmido por cromatografia gasosa. O estudo de localização de 2010, do mesmo instituto, descreveu 29,2 nmol por grama no cérebro inteiro, 38,9 no córtex e 126,4 no hipocampo, com cerca de 60 por cento do péptido na fração subcelular nuclear. Não foi localizada nenhuma replicação independente.
A cicloprolilglicina modula os recetores AMPA?
Um estudo de eletrofisiologia indica que sim. Em 2016, um grupo de Moscovo mediu correntes AMPA transmembranares aumentadas em células de Purkinje do cerebelo de rato a uma concentração de um micromolar e descreveu o péptido como um modulador endógeno positivo. Não foi publicada nenhuma afinidade de ligação, e o resultado não foi reproduzido por um laboratório independente.
A glicina-prolina cíclica é a mesma molécula que a cicloprolilglicina?
Sim, os dois nomes descrevem o mesmo dipéptido cíclico. Um grupo de investigação da Nova Zelândia estuda-o como metabolito do fator de crescimento semelhante à insulina 1 e como biomarcador plasmático, enquanto um grupo russo o estuda como metabolito nootrópico. As duas literaturas usam nomenclatura diferente, ensaios diferentes e redes de citação em grande parte separadas.
A hipótese de pró-fármaco do noopept foi replicada de forma independente?
Não em sentido estrito. Quase todo o trabalho primário que aponta este metabolito como a espécie ativa provém de um único instituto de Moscovo e surge em duas revistas traduzidas. Um estudo independente de 2022 em fatias verificou que o próprio dipéptido original atua através de recetores nicotínicos alfa7, o que se coaduna mal com a ideia de que seja apenas um transportador.
References
- Gudasheva et al., FEBS Letters, 1996 – cicloprolilglicina no cérebro de rato
- Gudasheva et al., Eur J Drug Metab Pharmacokinet, 1997 – principal metabolito do GVS-111
- Boiko et al., Bull Exp Biol Med, 2010 – localização no cérebro de rato
- Gudasheva et al., Dokl Biochem Biophys, 2016 – modulador positivo dos recetores AMPA
- Gudasheva et al., Dokl Biochem Biophys, 2020 – efeito ansiolítico, AMPA e TrkB
- Gudasheva et al., Dokl Biochem Biophys, 2022 – neuroproteção, AMPA e TrkB
- Zainullina et al., Bull Exp Biol Med, 2020 – atividade proliferativa celular
- Kondratenko et al., Neuroscience Letters, 2022 – recetores nicotínicos alfa7 em CA1
- Kolyvanov et al., Bull Exp Biol Med, 2022 – metabolismo do GZK-111 em ratos
- Guan et al., Scientific Reports, 2014 – a glicina-prolina cíclica regula a homeostase do IGF-1
- Fan et al., Ann Clin Transl Neurol, 2019 – razão plasmática em doentes com AVC
- Fan et al., Nutrients, 2018 – glicina-prolina cíclica no líquido cefalorraquidiano
Exclusivamente para investigação. A Nonsensia fornece padrões de referência analíticos para aplicações laboratoriais e de investigação. Este artigo é publicado para fins científicos e educativos. Não constitui aconselhamento médico, não descreve qualquer utilização em seres humanos e nada nele deve ser entendido como recomendação para administrar qualquer substância a uma pessoa ou animal.
Arquivado em: Investigação em nootrópicos
Este artigo faz parte do nosso guia sobre A base de evidência dos compostos de investigação em cognição: um guia crítico.
The compound discussed in this article is available as an analytical reference standard: Noopept (Omberacetam) ≥99% HPLC – Analytical Reference Standard | CAS 157115-85-0.